Takeda Pharmaceutical Co. Ltd. has agreed to pay Molecular Templates Inc. $30 million up front and potential milestone payments of as much as $632.5 million should the Austin, Texas-based company choose to co-develop CD38-targeted engineered toxin bodies (ETB) for the treatment of patients with diseases such as multiple myeloma. News of the deal lifted Molecular Templates' shares (NASDAQ:MTEM) 52.4 percent higher on Wednesday to $6.25.